underappreci factor viia stori time move
novoseven initi coverag
outperform pt
initi coverag cbio outperform rate price target
view cbio offer uniqu approach two import question
hemophilia best method transit inhibitor patient product
design treat bleed prophylaxi prevent bleed best
treat pediatr hemophilia patient candid subcutan
non-factor replac therapi gene therapi believ mani investor
current overlook potenti benefit compani subcutan factor
viia program particularli factor vii defici patient hemophilia inhibitor
patient expect stori solidifi offer materi upsid cbio
share independ binari factor ix readout
believ mani investor incorrectli character target market
marzaa factor viia hemophilia inhibitor patient increasingli serv
subcutan hemlibra hemophilia inhibitor patient import
market marzaa view hemophilia inhibitor patient factor vii
defici patient collect sizabl market treat
interim phase ii data marzaa suggest anti-drug antibodi question
surround dalca factor ix issu marzaa low inject
site reaction rate support healthi patient complianc believ
profil support expand use beyond hemophilia inhibitor patient
indic novoseven recombin iv factor viia wide use
model call cbio recogn marzaa revenu
gross sale base posit phase data launch
hemophilia inhibitor patient label use account largest
contributor forecast
upbeat invest thesi share cbio base least part
expect hemophilia patient place particularli high premium
product safeti profil factor replac therapi product reli
relat mechan action best posit demonstr accept
safeti prophylaxi
cautious optimist develop anti-drug antibodi phase ii
dalca factor ix like relat structur modif intend extend
half life drug view continu develop viabl
risk develop anti-drug antibodi potenti line recombin
year price histori cbio
develop drug
marzeptacog
subcutan factor ix complet
phase ii develop hemophelia
analyst certif import disclosur see disclosur
indic
view investor underestim address
market subcutan marzaa includ factor vii defici
acquir hemophilia
novoseven standard care thesi assum investor
assign valu expand marzaa market opportun
follow present preclin feasibl data
confirm expand develop plan phase
hemophilia inhibitor data confirm safeti pk profil
posit phase iib data dalca evid
anti-drug antibodi could provid upsid outlook
central valuat
marzaa subcutan factor viia approv drug
base clean advers event profil attract pk/pd
character activ factor replac
investor expect dalca low result favor upside/
downsid outlook phase iib cohort
marzaa approv use hemophilia patient inhibitor
drug use label indic novoseven
recombin factor viia standard care
combin clean phase iib data fda clearanc us ind
mitig investor concern dalca immunogen profil
either dalca marzaa partner market outsid us
provid independ valid commerci market opportun
cbio expand marzaa develop plan includ two
addit indic
setback develop gene therapi treatment hemophilia
 reset investor expect sustain subcutan factor
februari phase ii marzaa data eahad meet confirm
toler profil phase dose
juli dalca phase iib data isth clarifi anti-drug antibodi
disclosur preclin
feasibl clinic
develop strategi marzaa addit indic includ
believ expect dalca low evid anti-
drug antibodi phase iib studi could neg investor
extend dose rais question regard use
fda requir addit preclin test prior approv
ind dalca result delay phase timelin
unabl scale product bulk drug product
dalca marzaa
price target base dcf analysi assum discount rate million share fulli dilut basi termin year
long-term growth rate
risk clinic trial failur phase marzaa program hemophilia patient inhibitor delay file ind dalca
treatment hemophilia due immunogen profil disrupt manufactur suppli chain includ scale marzaa
dalca gene therapi becom establish standard care quickli expect wide use pediatr patient
initi outperform pt
subcutan non-factor replac
initi coverag catalyst bioscienc inc outperform rate
price target view cbio emerg hematolog stori uniqu approach
address two import question hemophilia treatment best method
transit inhibitor patient product treat bleed event prophylaxi
prevent bleed best treat pediatr hemophilia patient
therapi potenti gene
therapi upbeat invest thesi share cbio base least part
expect hemophilia patient place particularli high premium
product safeti profil factor replac therapi product reli
relat mechan action best posit demonstr accept safeti
prophylaxi cbio pipelin built develop subcutan formul factor
viia marzeptacog alfa activ marzaa factor ix dalcinonacog alfa dalca
treat clinic import subset hemophilia hemophilia inhibitor patient
suitabl altern prophylaxi strategi
expect peak sale marzaa factor viia dalca factor ix
model call cbio commerci product us seek partner
market regard near-term news flow see two materi catalyst
present phase iib subcutan dalca factor ix focu resolv
question anti-drug antibodi observ phase ii develop present
phase ii marzaa factor viia data eahad februari pt base
dcf analysi assum discount rate million share fulli dilut basi
termin year revenu growth rate
marzaa underappreci factor viia asset alon support upsid stock
believ mani investor incorrectli character target market marzaa
factor viia hemophilia
increasingli serv
subcutan hemlibra hemophilia inhibitor patient import market
marzaa view hemophilia inhibitor patient factor vii defici patient
collect sizabl market treat hemlibra patient
relev competit product iv novoseven rt coagul factor viia
recombin view view potenti marzaa displac novoseven
becom clear cbio manag outlin strategi line expans
marzaa beyond hemophilia
past six month cbio releas interim phase ii data marzaa
program suggest anti-drug antibodi question surround dalca
issu marzaa low inject site reaction rate support healthi
patient complianc believ profil support expand use drug beyond
hemophilia inhibitor patient indic novoseven wide use
includ factor vii defici acquir hemophilia note exhibit novoseven
use label numer indic evalu activ complet
marzaa offer sale primarili hemophilia label use
marzaa design combin increas potenc durat activ support
subcutan prophylaxi hemophilia patient inhibitor hemlibra
first subcutan product approv treatment inhibitor patient expect marzaa
carv import nich base known safeti profil factor
replac therapi report case thrombot advers event
potenti treat hemophilia patient inhibitor hemlibra activ
hemophilia patient addit upbeat outlook cbio base least part
expect factor replac product remain standard care
hemophilia hemophilia prophylaxi us least anoth ten year base
confirm safeti profil recombin factor replac slow adopt
gene therapi base need fulli character advers event profil includ safeti
profil follow re-dos technic challeng relat gene deliveri
net forecast call launch marzaa drug captur
us hemophilia inhibitor market driven primarili penetr hemophilia
inhibitor patient intern market expect modest market share
base limit qualiti hemophilia infrastructur outsid us expect
product sold partner cbio recogn econom equival
gross sale expect marzaa price annual us
jurisdict view line annual cost associ
exist on-demand factor viia model call cbio recogn sale
gross sale
dalca factor ix sq second commerci model sale
dalca factor ix sq earlier develop compani factor viia
program potenti address market smaller view product may
enjoy stronger competit posit base limit direct competit dalca
develop daili subcutan prophylaxi sever hemophilia potenti
best-in-class molecul differenti three structur variant improv biolog
properti factor ix enabl subcutan dose versu iv standard-of-car
believ dalca potenti first-to-market subcutan factor replac product
hemophilia patient model call peak gross sale potenti
hemophilia prophylaxi base daili dose profil
anti-drug antibodi cloud factor ix break
june two patient receiv dalca develop anti-drug antibodi result
reduc factor express patient success rescu wild-typ factor
ix event rais regulatori commerci concern regard outlook
dalca decemb company-sponsor event manag present
result sever analyt analysi potenti immunogen profil compar
benefix result hla type confirm two patient cousin
hla type t-cell prolifer mapp peptid suggest structur dalca
relat peptid demonstr immunogen profil gener compar
benefix view analysi import partial pictur potenti
immunogen profil specif dalca benefix compar
profil two patient develop anti-drug antibodi dalca also receiv benefix
develop anti-drug antibodi benefix sound explan
differ would note differ protein fold result differ
immunogen respons molecul ident structur
base addit inform cautious optimist develop anti-drug
antibodi phase ii like relat structur modif intend extend
half life dalca view continu develop viabl risk
develop anti-drug antibodi gener line recombin product
howev believ avail data allow cbio identifi specif hla type
patient characterist stratifi patient high low risk anti-drug
antibodi across clinic trial approv hemophilia treatment anti-drug antibodi
rate given small size hemophilia studi six patient
phase iib view absolut risk anoth anti-drug antibodi event low
price target share cbio base discount cash flow dcf
model sale factor viia factor ix subcutan prophylaxi hemophilia
includ contribut pipelin program
model call compani maintain us commerci right program
expect cbio partner hemophilia asset geographi cbio receiv
net royalti expect compani achiev profit begin
pay tax effect tax rate
forecast call peak gross factor viia sale last year
dcf model roughli revenu us sale factor ix program
contribut termin year primarili us peak sale
final year dcf valuat forecast free cash flow driven
primarili us hemophilia sale appli discount rate long-term revenu
growth rate fulli dilut share count million
oppenheim co inc estim compani document
view discount rate bp typic discount rate
compani lead program pivot clinic trial appropri given elev
commerci risk associ highli competit long-act factor replac
market potenti competit altern therapeut modal includ gene
therapi unresolv question regard anti-drug antibodi dalca
account two-third revenu termin year forecast
long-term revenu growth rate line standard long-term growth rate
biotechnolog compani share count million includ million
model call cash balanc fund oper increment capit
requir roughli achiev profit
discount revenu dilut share oppenheim co inc estim compani report incom work free cash growth cash catalyst bioscienc inc
cbio typic provid import clinic updat three medic meet year
european associ haemophilia alli disord eahad februari
intern societi thrombosi haemostasi isth american societi
hematolog decemb expect eahad import
present marzaa potenti updat dalca isth view updat
oppenheim co inc estim compani document
specif expect cbio provid overview complet marzaa phase ii
cohort eahad februari expect present confirm
recommend dose phase develop demonstr clean immunogen
profil demonstr greater reduct annual bleed rate abr
less manag also guid present least one
addit preclin studi cautious optimist preclin data describ
profil marzaa model factor vii defici present data marzaa
indic outsid hemophilia patient inhibitor critic invest
thesi potenti marzaa target larger market investor current
term phase iib updat dalca measur success
straightforward time uncertain view believ demonstr clean
immunogen profil episod anti-drug antibodi primari metric
success cbio announc plan decemb re-initi clinic develop
exact time dose first patient still uncertain view sequenti
enrol prudent fulli character immunogen small phase iib
studi believ present data isth juli feasibl time could slip
decemb
separ expect cbio meet fda discuss phase design
dalca manag guid six month prophylact dose confirm
endpoint target patient enrol may also serv import catalyst cbio
lastli note invest thesi believ commerci partner may
acrit compon valu creation next sever year
visibl timelin specif event believ complet deal could serv
import catalyst cbio share
corpor histori busi model
compani form catalyst bioscienc inc develop proteas
treatment complement disord portfolio coagul factor current
busi model base primarili potenti deliv factor replac therapi
conveni extend releas product achiev higher
factor express level current replac therapi
eventtim importancepresent marzaa phase ii data eahadfebruari patient dose dalca phase iib phase iib data isthjuli fda confirm phase dalca studi feasibl data marzaa factor vii cbio outperform
take expect certain segment hemophilia market prefer factor
replac gene therapi howev progress gene therapi product potenti
hemophilia patient achiev normal factor express greater shift
emphasi cbio factor replac pipelin toward develop product
higher express level conveni alon offer adequ differenti
compani sign agreement wyeth subsequ merg
factor viia base primarili partnership compani enter
revers merger agreement targacept inc march list share
april notifi catalyst termin agreement due
intern pipelin review accord compani
merger complet august catalyst bioscienc surviv
entiti share trade symbol cbio legaci targacept holder receiv
aggreg princip amount redeem convert note outstand
march cash net legaci targacept sharehold
receiv ownership combin compani exchang cash
upon complet merger cbio complet restructur support intern clinic
develop factor viia includ pipelin priorit result de-priorit
complement disord personnel reduct re-capit compani
specif cbio divest non-hemostasi asset shelv preclin factor xa
program april howard levi join chief medic offic lead clinic
develop strategi includ design plan factor viia pivot phase ii/iii studi
transfer manufactur process
pursuant cbio agreement isu abxi south korean pharmaceut compani
isu abxi conduct fund phase i/ii develop factor ix sq cbio retain
world-wide exclus right program exclud south korea respons
futur develop manufactur commerci
lastli mention cbio effect re-capit compani
underwritten equiti offer unit prefer share april proce
fund factor viia clinic develop support continu invest factor ix
believ manag turnaround strategi well align outlook
compani current sharehold
clinic overview hemophilia
hemophilia x-link congenit bleed disord caus reduc express
one blood clot factor gene clinic practic hemophilia
typic relat factor ix defici focu cbio collabor isu
abxi account approxim hemophilia case hemophilia
relat factor viii defici account case
american diagnos hemophilia accord nation hemophilia
foundat roughli two-third new case male birth matern carriescdc
estim hemophilia occur male birthswith remaind due
spontan mutat intern world feder hemophilia estim
nearli peopl live hemophilia believ number
conserv given low rate diagnosi especi among develop nation
current effect disease-modifi therapi limit prophylact
option result nearli patient treat recombin replac
therapi via iv infus therapi effect children particular
issu venou access at-hom self-administr use implant venou
access devic optim prophylaxi due risk surgeri local infect
thrombosi accord world feder hemophilia american
hemophilia patient year younger patient year
age patient year old
take nearli half hemophilia patient age pediatr patient
particular challeng complianc iv dose regimen good
candid gene therapi believ pediatr patient offer
attract market subcutan factor replac therapi
importantli previous untreat hemophilia patient
hemophilia patient develop immunolog respons replac therapi
typic within first exposur day translat estim
inhibitor patient global vast major factor viii inhibitor
standard-of-car factor inhibitor patient includ immun toler induct
high-dos factor viii factor ix patient return normal factor viii
factor ix replac therapi follow treatment patient fail longer
respond factor replac therapi receiv bypass agent anti-inhibitor
coagul complex recombin factor viia on-demand
sever hemophilia occur hemophilia patient sever diseas
attribut level clot factor defici sever patient suscept
bleed episod per week bleed commonli spontan often occur joint
muscl lead signific morbid absenc treatment sever
hemophilia patient typic die age us develop nation
strong hemophilia diagnosi protocol global hemophilia patient
diagnos accord world feder hemophilia
exhibit hemophilia stage base factor express level
current world feder hemophilia treatment guidelin call lifelong factor
replac prophylaxi patient sever hemophilia reduc annual bleed rate
abr prophylaxi design maintain trough factor activ moder
hemophilia tabl associ significantli lower rate spontan
bleed patient mild moder hemophilia may opt prophylaxi activ
monitor on-demand factor replac treatment
gener movement among hematologist particularli us toward
seek therapi offer higher trough level limit consensu regard
altern target world feder hemophilia threshold
exhibit common area hemophilia bleed
first gener recombin factor ix product requir iv infus time per
week maintain factor ix activ sever patient newer extend half-lif
factor replac product aprolix idelvion reduc dose frequenc
weekli longer iv infus achiev materi higher trough level
next-gener factor replac product cbio factor ix sq subcutan
program seek reduc treatment burden improv qualiti life maintain
similarli high factor ix trough level addit sever compani explor factor
ix gene therapi may offer longer durat benefit
regard inhibitor market multipl compani explor subcutan factor
viia well novel mechan action enabl prophylaxi includ use bi-
specif antibodi tissu factor pathway inhibitor tfpi
severitydescriptionnorm world feder hemophilia hemophilia base clot factor levelspercentag normal factor activ bloodnumb iu/dl whole bloodmild bleed result surgeri major injuri moder per month may bleed long time surguri injuri dental work spontan bleed rare sever per week frequent joint muscl bleed bleed often spontan site bleedhemarthrosismor common hing jointsless common multi-axel major nervou world feder hemophilia bleed locat frequenc catalyst bioscienc inc
take expect subset younger activ patient switch daili
subcutan product avail gene therapi may eventu offer altern
patient long-term efficaci unproven view
cbio next-gener factor viia sq program marzaa factor viia variant
develop primarili subcutan prophylaxi hemophilia inhibitor patient cbio
factor viia sq program design combin increas potenc durat
activ vivo support subcutan prophylaxi hemophilia patient inhibitor
importantli present major hematolog meet demonstr daili
subcutan factor viia achiev steady-st blood level factor viia suffici
correct baselin coagul impair hemophilia mice hemophilia dog
specif whole blood clot time aptt second data
confirm interim analysi hemophilia patient treat phase ii
cbio conduct global phase ii/iii studi evalu factor viia sq prophylaxi
hemophilia patient inhibitor open-label phase ii portion near
complet dose enrol adult hemophilia patient
without inhibitor addit phase ii data expect earli februari
eahad meet drug differenti pk/pd subcutan deliveri approach
support fda orphan drug design
background pfizer collabor
june cbio enter licens agreement wyeth develop human factor
viia product cbio grant wyeth exclus world-wide licens technolog
april subsequ wyeth merger agreement termin
effect decemb pursuant termin agreement grant cbio
exclus right manufactur materi process relat factor
cbio continu econom oblig includ develop
regulatori commerci mileston single-digit royalti net salesour estim
accord manag mileston payment weight toward commerci
event accord cbio termin due intern pipelin review
februari eahad meet cbio present import data confirm
favor pk profil marzaa dog model poster entitl pharmacokinet
hemophilia dog research evalu dose factor viia sq dose
daili day hemophilia dog model drug half-lif hour
bioavail daili dose factor viia sq produc compar whole
blood clot time g/kg iv formul g/kg iv novoseven
marzaa appear achiev steadi state concentr roughli three day
gener consist pk profil intraven formul
take import data provid linkag pk profil iv subcutan
formul believ data support potenti daili subcutan dose vivo
exhibit pk profil factor viia sq similar iv dog model
levi et al pharmacokinet pharmacodynam daili subcutan administ marzeptacog alfa hemophilia dog
sq formul build prior develop iv formul also
demonstr extend half-lif isth present safeti pk/pd data
open-label phase studi evalu singl ascend dose factor viia iv pf-
adult male sever hemophilia without inhibitor
studi enrol hemophilia patient patient prior histori inhibitor factor
viii factor ix replac therapi subject prior exposur
patient underw washout hemostat treatment hour prior dose
non-bleed state single-dos factor viia iv administ ug/kg
ug/kg ug/kg one patient receiv factor viia iv
prior protocol amend object safeti pk/pd surveil
antibodi immun respons conduct baselin day post-dos
exhibit phase pk profil iv formul
gruppo et al safeti pharacokinet pharmacodynam recombin fviia variant result singl ascend dose
phase studi hemophilia subject isth
describ exhibit clearanc volum distribut steadi state decreas
ug/kg dose remain rel stabl ug/kg
dose termin half-lif hour consist across dose level
exhibit highlight observ dose-depend transient shorten activ partial
time dose-depend increas tga peak tga etp prothrombin fragment
arithmet mean cv paramet except tmax median catalyst bioscienc inc
thrombin-antithrombin tat find consist
expect dose-depend improv clot potenti reduct bleed
exhibit pharmacodynam profil single-dos factor viia iv bolu
gruppo et al safeti pharacokinet pharmacodynam recombin fviia variant result singl ascend dose
phase studi hemophilia subject isth
respect safeti factor viia iv well toler importantli
observ antibodi immun respons thrombosi total
hemophilia-rel teae includ arthralgia
joint swell flank pain muscl swell
overal non-hemophilia-rel teae report common
event event dizzi hematoma headach oropharyng pain
cbio conduct global registr phase ii/iii studi evalu marzaa prophylaxi
hemophilia patient inhibitor open-label phase ii portion expect
complet enrol come week enrol adult hemophilia patient
without inhibitor interim phase ii data expect
enrol patient receiv single-dos factor viia iv follow exposur day
marzaa patient breakthrough bleed receiv escal dose marzaa
achiev exposur day breakthrough bleed primari endpoint trial
includ abr versu record histor abr breakthrough bleed requir dose
clinic trial conduct contract research organ inc research
part studi g/kg dose infus iv subject
pharmacokinet coagul measur addit dose altern
method deliveri g/kg given
pharmacokinet bioavail coagul paramet measur
subject subcutan
interim phase ii data demonstr reduct abr
part studi includ daili subcutan administr marzaa g/kg
day follow safeti follow-up week last dose spontan
bleed occur spontan bleed occur dose escal
g/kg day
meet decemb seven patient enrol studi
median abr highlight studi includ five subject demonstr
clinic signific reduct abr complet dose subject
bleed final dose exhibit half-lif subcutan inject
marzaa hour anti-drug antibodi observ
exhibit interim phase ii marzaa data
howard levi levani makhaldiani genadi iosava johnni mahlangu marina kosinova heghin khacchatryan frank del greco frank
mcl booth phase trial subcutan administ marzeptacog alfa activ engin fviia hemophilia inhibitor
pharmacokinet pharmacodynam safeti efficaci dec annual meet
view market new hemophilia product treat inhibitor patient competit
numer larg compani pursu novel mechan action design provid
subcutan prophylaxi expect safeti remain top consider
patient believ best new product base proven mechan action
 factor replac therapi may enjoy faster physician patient accept
near term product offer novel mechan action increment
improv dose frequenc
take factor replac therapi remain domin treatment modal
least next year gene therapi may eventu offer altern on-going
challeng regard deliveri gene therapi applic tissu need
character safeti profil prior regulatori approv materi barrier target
organ size children pose addit challeng
addit potenti new market entrant explor novel mechan
prophylax inhibitor patient new approach includ bi-specif antibodi
roch rnai anti-tfpi hemlibra view offer signific improv
current avail inhibitor prophylaxi everi day infus
plasma-bas feiba howev hemlibra applic hemophilia inhibitor
seriou thrombot advers event report phase
exhibit highlight extrins coagul pathway requir mechan achiev
hemostasi inhibitor patient differ approach develop gener
factor viia product seek reduc cross-talk intrins coagul pathway
altern strategi target downstream feedback loop
exhibit intrins extrins pathway coagul
current inhibitor market consist two drugsnovoseven feiba novoseven
rfviia avail on-demand therapi due half-lif limit feiba
approv everi day iv prophylaxi despit limit novoseven
feiba peak gener roughli annual sale
take marzaa offer improv dose flexibl compar iv novoseven
potenti displac product hemophilia patient inhibitor indic
novoseven wide use
novoseven iv administ recombin factor viia protein design promot
hemostasi activ extrins pathway coagul cascad specif
factor viia complex tissu factor activ coagul factor factor xa
well coagul factor ix factor ixa factor xa complex factor
convert prothrombin thrombin lead convers fibrinogen fibrin local
hemostasi despit signific commerci limit lack activ drug patent
key market includ us japan sale
novoseven first approv fda indic treatment
bleed episod periop manag adult children hemophilia
 inhibitor patient congenit factor vii defici glanzmann thrombasthenia
refractori platelet transfus without antibodi platelet base short
half-lif hour hemophilia patient novoseven dose iv everi hour
hemostasi achiev
novoseven approv bleed episod associ congenit hemophilia
 inhibitor acquir hemophilia congenit factor vii glanzmann
thrombasthenia product also approv periop manag
asid approv indic novoseven also investig
indic multipl clinic trial exhibit indic includ variou
form hemorrhag intracrani intracerebr postpartum hemorrhag
shock burn trauma myocardi ischemia bleed during/follow surgeri
novoseven activ recombin factor vii investig intervent
trial variou stage progress multipl outcom list
exhibit clinic trial investig novoseven activ recombin fvii
believ altern factor replac therapi reach market
provid potenti less frequent dose develop timelin like
extend due need fulli character safeti profil particularli among
cbio outperform
weekli bi-weekli prophylaxi
roch japanes partner chugai pharmaceut develop hemlibra
emicizumab human bi-specif antibodi target factor ixa factor
collect replic co-factor function fviii mechan action requir
activ factor ix intrins pathway therefor suitabl
hemophilia inhibitor non-inhibitor patient
efficaci conveni subcutan dose like attract
mani hematologist view safeti profil may limit initi uptak specif
novemb roch announc four patient studi hemophilia
event two thrombot microangiopathi tma four patient treat
breakthrough bleed feiba recent februari roch disclos
death patient follow two seriou advers event patient
experienc seriou rectal hemorrhag treat feiba subsequ
patient develop tma patient die result hemorrhag preliminari
analys indic characterist tma consist observ two
take caus thrombot microangiopathi tma case phase
develop fulli character may relat hemlibra
seriou event caus safeti overhang may restrict initi adopt
alnylam phase develop fitusiran subcutan administ once-
monthli prophylaxi hemophilia patient without inhibitor small
interf rna rnai therapeut design inhibit antithrombin liver-
express plasma protein inactiv thrombin coagul factor
phase atla program evalu fitusiran multipl studi includ
atlas-inh sever hemophilia hemophilia patient inhibitor
atlas-a/b sever hemophilia hemophilia patient without inhibitor
atlas-ppx sever hemophilia hemophilia patient without
inhibitor switch prophylact factor therapi bypass agent therapi
fitusiran endpoint like includ abr bypassing/factor replac use
qualiti life safeti
take fitusiran offer differenti mechan plausibl limit
clinic valid preliminari data suggest fitusiran patient continu requir
factor therapi treat breakthrough bleed
sever compani develop product target anti-tissu factor pathway inhibitor
tfpi pathway subcutan prophylaxi hemophilia inhibitor patient tfpi
multival proteinas inhibitor identifi inhibitor extrins
coagul cascad specif tfpi block format tissu factor activ factor
viia tf-fviia prevent activ factor factor xa
activ factor factor xa intrins pathway factor viiia/factor
ixa complex counteract tfpi activ non-hemophilia patient awar three
bayer
take tissu factor pathway offer eleg altern pathway achiev
subcutan dose rang hemophilia patient still earli develop
view group may eventu offer direct competit cbio factor viia
revenu modelpeak sale
marzaa revenu forecast base sale hemophilia inhibitor prophylaxi
includ potenti use on-demand set due high likelihood cbio
seek premium price short-act iv factor viia replac addit
includ sale addit popul factor vii defici patient base
limit clinic data
estim us hemophilia patient live inhibitor assum
growth in-lin overal popul annual global hemophilia
inhibitor patient factor viii inhibitor hemophilia inhibitor
accord world feder hemophilia identifi us hemophilia
inhibitor market patient hemophilia inhibitor market patient
intern world feder hemophilia estim roughli hemophilia
patient live inhibitor suggest hemophilia hemophilia
patient expect intern hemophilia popul increas annual
driven part improv diagnosi rate region brazil russia
model call cbio marzaa captur hemophilia inhibitor
market driven primarili penetr hemophilia inhibitor patient
intern market expect modest market share base limit qualiti
hemophilia infrastructur outsid us expect product sold partner
cbio recogn econom equival gross sale
expect marzaa price annual us
jurisdict view line annual cost associ exist on-
demand factor viia model assum marzaa dose continu throughout
model call cbio launch marzaa us row
respect model call cbio recogn sale gross
sale
methodolog point account marzaa royalti cog
reduct gross revenu
cbio next-gener factor ix sq program dalca factor ix variant
develop daili subcutan prophylaxi sever hemophilia drug also
known cb potenti best-in-class molecul
differenti dalca contain three point mutat two loop within
protein design improv biolog properti factor ix enabl subcutan
believ dalca potenti first-to-market subcutan factor replac product
hemophilia patient model call peak gross sale potenti
hemophilia prophylaxi base daili dose profil
compani factor ix proteas variant includ dalca develop intern
use cbio proprietari ration design strategi focus iter amino acid
substitut drive improv biolog properti specif dalca variant three
resist inhibit atiii
increas affin factor viiia multi-fold increas catalyt activ versu wild-
hemophilia inhibitor market modeltot hemophilia inhibitor populationproject growth hemophilia inhibitor number hemophilia inihitor inhibitor patient hemophilia hemophilia inhibitor hemophilia inhibitor popul receiv marzeptacog hemophilia inhibitor patient inhibitor patient hemophilia hemophilia inhibitor hemophilia inhibitor popul receiv marzeptacog hemophilia inhibitor patient total inhibitor popul receiv marzeptacog total inhibitor patient treatment increas annual sale marzeptacog alfa hemophilia market modeltot row hemophilia inhibitor popul project growth hemophilia number row hemophilia total inhibitor popul receiv marzeptacog patient treatment price per row sale marzeptacog alfa revenu marzeptacog alfa cbio world-wide marzeptacog alfa revenu marzeptacog alfa revenu catalyst bioscienc inc
exhibit improv potenc factor ix sq compar wild type
levi et al pharmacokinet pharmacodynam daili subcutan administ hemophilia dog poster
cbio partner program south korean biosimilar manufactur isu abxi
develop manufactur process perform ind-en toxicolog human proof-
of-concept studi collabor detail outlin
south korean phase i/ii safeti pk/pd studi fund isu dose first patient
june gener import proof-of-concept data dose
final cohort phase ii develop discontinu two patient develop anti-
drug antibodi follow review variou immunogen model decemb
cbio announc plan restart clinic develop phase iib studi
take dalca potent molecul base preclin clinic model steady-
state express occur dose day overal would view daili factor ix sq
trough factor ix activ level mild hemophilia suffici support
pivot develop futur develop requir clean anti-drug antibodi profil
background isu abxi collabor
mention septemb cbio enter co-develop agreement
isu human factor ix isu respons conduct fund develop
manufactur factor ix product complet phase i/ii clinic trial
time complet phase develop isu right first refus
commerci factor ix south korea isu exercis
regard econom structur agreement cbio receiv up-front
elig receiv clinic mileston product agreement
commerci isu exercis option commerci south korea cbio
requir pay isu global net profit relat factor ix
decemb cbio disclos amend partnership elimin profit
share option exchang clinic regulatori sale mileston isu
also receiv undisclos single-digit royalti global sale estim
take view remov isu profit share option make dalca
attract potenti partner buyer
preclin data point high factor ix express
preclin character dalca present eahad
meet data suggest improv bioavail potenc compar
commerci recombin factor ix benefix potenti subcutan dose
hemophilia prophylaxi importantli hemophilia dog normal minipig
dalca achiev stead-stat plasma level suffici correct sever hemophilia
normal rang day hemophilia mice stead-stat plasma level suffici
correct mild time period
multipl dose factor ix sq hemophilia dog model
dalca daili inject hemophilia dog day blood sampl
includ whole blood clot time wbct aptt collect hour
factor ix antigen measur elisa
term anti-hemophilia activ wbct exhibit decreas
minut baselin minut red green minut hour normal
control dog blue wbct minut wbct reduct dalca dose
peak minut minut hour respect benefit
persist minut hour post-fin dalca dose hour
factor ix antigen progress increas subsequ dose level
correl calcul factor ix activ
hour respect exhibit tmax achiev hour bioavail
factor ix sq half-lif hour base single-phas versu iv alpha-
phase half-lif hour beta-phas valu hour respect safeti
emerg clinic advers event abnorm chemistri lab abnorm observ
take dalca achiev steady-st activ suffici correct sever hemophilia
normal hemophilia dog day dose believ clinic viabl
exhibit dalca multi-dos pk/pd profil hemophilia dog
levi et al pharmacokinet pharmacodynam daili subcutan administ hemophilia dog poster
dalca vs benefix pk normal minipig
single-dos pk/pd portion minipig intraven dose current standard
care benefix dalca mg/kg blood sampl
collect hour post-iv
hour post-sq exhibit
multiple-dos portion studi minipig receiv daili dalca
day sampl collect
hour
factor ix antigen determin sandwich elisa activ calcul base
known factor ix antigen activ relationship hemophilia wherebi
dalca equal factor ix activ
exhibit pk profil iv versu sq minipig
hong et al pharmacokinet subcutan administ cb minipig compar benefix poster eahad
dalca demonstr dose-depend increas plasma factor ix antigen pk
profil similar benefix dose mass bioavail dalca
minipig versu benefix
dalca achiev steady-st activ suffici correct sever hemophilia normal
four day dose consist hemophilia dog model
take concord minipig dog model term time-to-steadi state
four day provid us increment confid pk/pd profil
exhibit pk profil multipl dose dalca normal minipig
hong et al pharmacokinet subcutan administ cb minipig compar benefix poster eahad
dalca vs benefix pk hemophilia normal mice
normal mice subcutan dose cbio factor ix mg/kg mg/kg
intraven dose mg/kg also administ benefix
dose sampl collect hour post-dos
similarli hemophilia mice receiv single-dos subcutan factor ix sq
mg/kg mg/kg daili dose sampl collect
hour dose mice inject volum factor ix
antigen measur sandwich elisa activ assess one-stag
pk profil subcutan factor ix sq benefix similar
dose-depend increas plasma factor ix antigen activ increas factor
ix sq dose howev given greater potenc factor ix sq benefix
factor ix activ level materi higher factor ix sq benefix equal
factor ix sq achiev steady-st activ suffici correct sever hemophilia mild
hemophilia hemophilia mice three day dose larg consist
hemophilia dog normal minipig figur bioavail factor ix sq
normal mice
take mous model suggest potenti greater potenc factor ix sq
exhibit pk/pd profil single- multiple-dos factor ix sq
hong et al pharmacokinet subcutan administ wild-typ hemophilia mice poster
factor viia phase i/ii proof concept
march cbio announc isu receiv ind approv korean ministri food
drug safeti initi first-in-human phase i/ii proof-of-concept studi evalu
dalca sever hemophilia patient phase i/ii studi fully-fund isu
cohort includ comparison benefix dose iu/kg iv
administ three particip cohort vari rout administr dalca
compar subcutan iv deliveri doubl dose administ
subcutan cohort receiv iu/kg cohort receiv iu/kg
dalca subcutan cohort multi-dos group receiv iu/kg dalca
daili six day
higgin et al combin sirolimu reduc anti-drug antibodi respons prolong drug exposur poster
cbio present data first three cohort phase i/ii studi dalca
hemophilia patient analysi focus cohort singl dose iu/kg sq
cohort singl dose iu/kg sq iu/kg sq factor activ
approach level achiev iv dose pool analysi cohort
indic dalca half-lif hour compar favor hour
current standard care long-act iv factor ix replac alprolix base cohort
data cbio skip cohort singl dose iu/kg sq move directli
cohort daili dose cohort dose iu/kg importantli pk/pd
model suggest load dose regimen ui/kg achiev factor ix
activ within seven day replic clinic trial dalca potenti first
product demonstr return normal level factor ix activ patient
elimin bruis microvascular bleed
eahad cohort suggest express possibl dalca
februari eahad cbio report posit data eahad meet
demonstr dalca record factor ix express level daili sq
formul six day importantli subject express level increas
steadili reach peak day six furthermor investig note collagen
yet fulli satur six day bioavail better day six
bioavail observ one dose net believ data strongli
suggest longer dose and/or includ iv load dose could result higher
peak express level observ eahad cohort
cohort stop due anti-drug antibodi
cohort includ dalca administ iv follow nine subsequ subcutan
daili dose studi design enrol particip
studi design phase iib
part updat data present catalyst bioscienc day decemb
manag outlin phase i/ii trial studi design reduc dose
concentr iu/kg iu/kg compar prior guidanc dose regimen
iu/kg iu/kg exhibit chang dose appli dalca
benefix respect cohort cohort maintain similar format
doubl dose concentr iu/kg given compar iu/kg
previous studi exhibit activ presenc neutral antibodi
measur determin effect dalca therapeut hemophilia
dalca factor ix revenu
factor ix sq revenu forecast base sale hemophilia prophylaxi
children includ potenti use on-demand set due high
likelihood cbio seek premium price short-act iv factor ix replac
believ adult particularli us eu well-defin pk-driven prophylaxi
protocol reluct chang treatment regimen last model segment
revenu us row us repres market opportun
base higher diagnosi rate better access prophylaxi therapi
american live hemophilia accord nation hemophilia
foundat assum us hemophilia popul grow line overal
popul annual roughli hemophilia patient diagnos
hemophilia result address us patient popul patient
includ target subset patient year age
younger accord world feder hemophilia
intern world feder hemophilia estim nearli peopl
live hemophilia expect intern hemophilia popul increas
annual driven part improv diagnosi rate region brazil russia
model hemophilia market patient base ratio
hemophilia patient base limit hemophilia diagnost infrastructur mani
develop nation assum fewer patient diagnos diseas earlier
life assum row hemophilia patient children compar
us
model call cbio factor ix drug captur target us hemophilia
market driven primarili subcutan dose conveni at-hom prophylaxi
intern market expect modest market share base limit
access prophylaxi price outsid us expect product sold
partner cbio recogn econom equival gross sale
expect dalca price annual us
jurisdict view line annual cost associ exist extend
half-lif factor ix replac prophylaxi model assum dalca dose
continu throughout patient life
believ daili subcutan dalca prophylaxi need demonstr median abr
less equal better alprolix sever hemophilia patient support
commerci believ patient will sacrific efficaci extra
model call cbio launch dalca us row forecast call
cbio recogn sale
methodolog point account factor ix royalti isu abxi oper
expens gross revenu recogn cbio
cbio manufactur product candid reli contract
manufactur clinic commerci suppli factor viia factor ix product
candid importantli cbio sign manufactur servic agreement well-
known third-parti supplier agc biolog symbiosi pharmaceut
servic ltd drug substanc manag complet manufactur technolog
transfer enabl product clinic suppli plan phase clinic trial
factor viia factor ix
respect cbio factor ix program isu abxi respons manufactur
complet phase i/ii clinic trial subsequ cbio began transfer bulk
api product expect begin produc drug substanc
factor ix program
take given potenc factor viia factor ix compound rel
small quantiti api requir support commerci launch
prior termin cbio commerci partnership respons
manufactur factor viia may cbio enter manufactur agreement
ico biolog inc renam biolog manufactur factor viia clinic
drug substanc fee-for-servic basi technolog transfer ico
complet cbio expect manufactur factor viia drug substanc
phase ii/iii clinic trial cbio intellectu properti develop
hemophilia market modeltot hemophilia popul project growth hemophilia number hemophilia hemophilia hemophilia hemophilia patient year hemophilia patient year hemophilia patient year popul target hemophilia popul receiv patient treatment increas annual sale dalca hemophilia market modeltot row hemophilia popul ex south korea project growth hemophilia number row hemophilia row hemophilia hemophilia hemophilia patient year popul target hemophilia popul receiv patient treatment increas annual row sale dalca revenu dalca cbio world-wide dalca revenu dalca revenu nation hemophilia foundat estim world feder hemophilia estim research servic get grip high- drug tool use juli catalyst bioscienc inc
specif relat factor viia agre total payment agc
initi statement work paid decemb
decemb cbio symbiosi pharmaceut servic enter fill-finish
manufactur servic agreement symbiosi manufactur factor viia drug product
clinic trial fee-for-servic basi cbio initi manufactur
technolog transfer symbiosi
februari compani contract agc biolog manufactur factor ix
phase develop commerci agreement includ total
payment initi statement work payment account
substanti portion forecast increas expens
believ cbio strong hemophilia intellectu properti posit across
factor viia factor ix clinic program includ composit matter method
manufactur novel factor variant februari compani control
patent includ issu us patent foreign grant accept patent
addit us patent applic addit pend foreign
compani global factor viia patent portfolio includ issu patent across
major hemophilia marketsunit state europ japancov modifi
factor viia polypeptid includ lead candid marzeptacog alfa activ
method produc modifi factor viia polypeptid term patient outsid
us cbio believ factor viia program strong patent protect least
base broad claim european patent ep entitl factor vii
polypeptid modifi use thereof importantli march
opposit period patent expir opposit clear threshold reduc
risk near-term challeng patent strengthen cbio overal intellectu
lastli factor viia program receiv fda orphan drug design
provid seven year exclus date fda approv base
current develop timelin expect durat potenti patent protect
exceed seven-year orphan drug exclus least two-thre year
cover global
encompass issu patent includ patent applic relat modifi
factor ix polypeptid includ cbio lead clinic candid compani three
issu us patent one us patent applic base current patent portfolio
expect factor ix enjoy us patent protect foreign coverag
drug also orphan drug design europ
cbio proteas develop identif technolog platform cover
patient includ seven applic maximum intellectu properti protect
us extend three addit patent includ two issu
us cover method identifi proteas cleav inactiv protein target
includ term adjust us patent expir
expect compani incur addit futur oper loss
achiev profit may gener addit tax asset off-set futur tax
oblig base financi project expect tax asset off-set
first year profit subsequ period expect
compani recogn effect tax rate
includ legaci feder state net oper loss carryforward
decemb financi model due potenti impair
follow april recapit
cbio develop stage compani view unlik gener materi
commerci product revenu view cbio eps-driven
stori encourag investor focu clinic develop regulatori mileston
cbio subcutan factor viia factor ix program primari avenu
creation sharehold valu
manag provid guidanc cash burn rate increas modestli
next month estim compani
initi product manufactur lot subcutan factor viia factor
ix program estim compani cash balanc adequ fund
oper exclud potenti impact busi develop
model includ potenti mileston payment relat factor viia
develop progress isu factor ix could increas cbio cash burn rate
given year exact time uncertain
sale expect compani begin receiv materi revenu potenti
commerci launch factor viia model assum compani recogn
revenu collect royalti revenu geographi
cog expect cbio next-gener hemophilia pipelin enjoy typic margin
biotech therapi around sale reach critic mass account cbio
single-digit royalti net sale factor viia product isu factor ix
 expect expens increas due
normal overhead spend follow recapit balanc sheet
middl move forward expect administr expens increas
annual rate
sale market expect cbio incur meaning sale market
expens model call compani hire sale peopl
support us launch factor viia
 forecast call spend acceler base spend
associ manufactur lot factor viia factor ix phase program
forecast call total spend versu
expect spend
ep expect cbio record ep exclud one-tim item
respect expect compani achiev profit
common stock catalyst bioscienc trade nasdaq capit market
ticker cbio compani underw signific
transform capit structur includ revers stock split februari
repay substanti convert debt april
financ recapit balanc sheet issuanc million common
share seri prefer stock convert million common share
warrant purchas million share compani subsequ complet two
secondari stock offer forc convers warrant substanti
septemb cbio million common share outstand
option convert million share common stock strike price current
market level fulli dilut share count million
compani outstand debt
decemb cbio employ full-tim employe includ six employe
engag manufactur clinic develop activ remaind focus
financ busi develop facil gener manag expect
compani maintain semi-virtu busi model first regulatori file
reli third-parti contract servic provid expect compani begin
invest us commerci structur support potenti launch fact viia
program invest begin earli
chief execut offic nassim usman serv ceo director cbio sinc
addit follow complet august revers merger also
name presid dr usman join compani morganthal ventur
remain ventur partner held variou senior execut level
 oper role ribozym pharmaceut subsequ sirna
therapeut acquir merck dr usman began
career massachusett institut technolog nih fogarti nserc
postdoctor fellow scientist depart biolog chemistri
author scientif articl name inventor issu patent
patent applic addit role cbio dr usman serv director
mosaic bioscienc receiv ph organ chemistri
mcgill univers
chief medic offic howard levi join compani april cbio
year pharmaceut experi focus benign hematolog
critic care therapeut area join cbio dr levi serv
consult numer public privat biotechnolog compani includ senior
global medic program bere respons clinic
develop single-chain factor viii senior vice presid
hemophilia start inspir biopharmacut addit dr
levi respons recombin factor viia clinic program
associ vice presid clinic research medic regulatori affair novo
nordisk dr levi held similar posit sangart focus dr levi
peer-review public chapter book member fellow
american colleg critic medicin receiv ch ph
univers witwatersrand carnegi mellon univers
chief financi offic fletcher payn serv cfo sinc join compani
januari mr payn year financi experi life
scienc industri includ cfo pathwork diagnost earlier career held
senior financi titl multipl public privat biotechnolog compani includ
cell genesi mr payn receiv haa school busi univers
california berkeley
compani report oppenheim co inc estim
research profit profit loss per share continu deriv incom loss loss per share averag common cbio outperform
compani report oppenheim co inc estim
short term restrict current properti account accru defer current portion long-term current defer equiti paid-in accumul comprehens accumul deficit sharehold catalyst bioscienc inc
stock price compani mention report
